Item 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

144K characters. Original on sec.gov · Markdown

Item 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA


Part I. Financial Information
Index
Item 1. Condensed Consolidated Financial Statements (Unaudited)			Page
Condensed Consolidated Statements of Income			5
Condensed Consolidated Statements of Comprehensive Income (Loss)			6
Condensed Consolidated Statements of Financial Position			7
Condensed Consolidated Statements of Changes in Equity			8
Condensed Consolidated Statements of Cash Flows			10
Notes to the Condensed Consolidated Financial Statements (Unaudited)			11
Note 1. Organization and Basis of Presentation			11
Note 2. Revenue Recognition			12
Note 3. Segment Information			13
Note 4. Receivables			14
Note 5. Financing Receivables			15
Note 6. Leases			15
Note 7. Acquisitions, Goodwill, and Other Intangible Assets			15
Note 8. Borrowings			16
Note 9. Postretirement Benefit Plans			17
Note 10. Income Taxes			18
Note 11. Accumulated Other Comprehensive Income (Loss) – Net			19
Note 12. Financial Instruments and Fair Value Measurements			20
Note 13. Commitments, Guarantees, Product Warranties, and Other Loss Contingencies			24
Note 14. Restructuring Activities			25
Note 15. Earnings Per Share			26
Note 16. Supplemental Financial Information			26
Note 17. Related Parties and Transition Services Agreement			29


Condensed Consolidated Statements of Income (Unaudited)
	For the three months ended September 30				For the nine months ended September 30
(In millions, except per share amounts)	2024		2023		2024		2023
Sales of products	$	3,201	$	3,186	$	9,454	$	9,530
Sales of services	1,662		1,636		4,899		4,816
Total revenues	4,863		4,822		14,353		14,346
Cost of products	2,033		2,076		6,045		6,197
Cost of services	805		811		2,378		2,383
Gross profit	2,026		1,935		5,930		5,766
Selling, general, and administrative	1,034		996		3,139		3,130
Research and development	316		322		967		890
Total operating expenses	1,350		1,318		4,106		4,020
Operating income	676		617		1,824		1,746
Interest and other financial charges – net	130		138		383		411
Non-operating benefit (income) costs	(102)		(94)		(306)		(332)
Other (income) expense – net	(9)		(63)		(1)		(85)
Income from continuing operations before income taxes	658		636		1,747		1,752
Benefit (provision) for income taxes	(168)		(250)		(435)		(550)
Net income from continuing operations	490		386		1,312		1,202
Income (loss) from discontinued operations, net of taxes	—		(4)		—		(4)
Net income	490		382		1,312		1,198
Net (income) loss attributable to noncontrolling interests	(19)		(7)		(40)		(33)
Net income attributable to GE HealthCare	470		375		1,272		1,165
Deemed preferred stock dividend of redeemable noncontrolling interest	—		—		—		(183)
Net income attributable to GE HealthCare common stockholders	$	470	$	375	$	1,272	$	982

Earnings per share from continuing operations attributable to GE HealthCare common stockholders:
Basic	$	1.03	$	0.83	$	2.79	$	2.17
Diluted	1.02		0.83		2.77		2.16
Earnings per share attributable to GE HealthCare common stockholders:
Basic	$	1.03	$	0.82	$	2.79	$	2.16
Diluted	1.02		0.82		2.77		2.15
Weighted-average number of shares outstanding:
Basic	457		455		456		455
Diluted	459		458		459		458

The accompanying notes are an integral part of these condensed consolidated financial statements.


Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

	For the three months ended September 30				For the nine months ended September 30
(In millions, net of tax)	2024		2023		2024		2023
Net income attributable to GE HealthCare	$	470	$	375	$	1,272	$	1,165
Net income (loss) attributable to noncontrolling interests	19		7		40		33
Net income	490		382		1,312		1,198
Other comprehensive income (loss):

Currency translation adjustments – net of taxes	177		(143)		70		(84)
Pension and Other Postretirement Plans – net of taxes	(67)		(264)		(138)		(346)
Cash flow hedges – net of taxes	(36)		22		(12)		(7)
Other comprehensive income (loss)	74		(385)		(80)		(437)
Comprehensive income (loss)	563		(3)		1,232		761
Less: Comprehensive income (loss) attributable to noncontrolling interests	19		(28)		40		(2)
Comprehensive income attributable to GE HealthCare	$	544	$	25	$	1,192	$	763

The accompanying notes are an integral part of these condensed consolidated financial statements.


Condensed Consolidated Statements of Financial Position (Unaudited)

	As of

(In millions, except share and per share amounts)	September 30, 2024		December 31, 2023
Cash, cash equivalents, and restricted cash	$	3,568	$	2,504
Receivables – net of allowances of $104 and $98	3,418		3,525
Due from related parties	6		32
Inventories	2,124		1,960
Contract and other deferred assets	1,046		1,000
All other current assets	476		389
Current assets	10,638		9,410
Property, plant, and equipment – net	2,539		2,500
Goodwill	13,138		12,936
Other intangible assets – net	1,132		1,253
Deferred income taxes	4,309		4,474
All other non-current assets	2,098		1,881
Total assets	$	33,855	$	32,454
Short-term borrowings	$	1,007	$	1,006
Accounts payable	2,911		2,947
Due to related parties	7		99
Contract liabilities	1,915		1,918
Current compensation and benefits	1,422		1,518
All other current liabilities	1,409		1,493
Current liabilities	8,670		8,981
Long-term borrowings	9,306		8,436
Non-current compensation and benefits	5,388		5,782
Deferred income taxes	59		68
All other non-current liabilities	1,920		1,877
Total liabilities	25,343		25,144
Commitments and contingencies
Redeemable noncontrolling interests	177		165
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 457,144,443 shares issued as of September 30, 2024; 455,342,290 shares issued as of December 31, 2023	5		5
Treasury stock, at cost, 291,053 shares as of September 30, 2024 and 0 shares as of December 31, 2023	(25)		—
Additional paid-in capital	6,551		6,493
Retained earnings	2,558		1,326

Accumulated other comprehensive income (loss) – net	(771)		(691)
Total equity attributable to GE HealthCare	8,317		7,133
Noncontrolling interests	18		12
Total equity	8,335		7,145
Total liabilities, redeemable noncontrolling interests, and equity	$	33,855	$	32,454

The accompanying notes are an integral part of these condensed consolidated financial statements.


Condensed Consolidated Statements of Changes in Equity (Unaudited)
	Common stock			Treasury stock
(In millions)	Shares	Amount		Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of June 30, 2024	457	$	5	—	$	—	$	6,540	$	2,101	$	(845)	$	16	$	7,817
Issuance of shares under equity awards, net of shares withheld for taxes and other	—	—		—	(25)		(10)		—		—		—		(35)
Net income attributable to GE HealthCare	—	—		—	—		—		470		—		—		470
Dividends declared ($0.03 per common share)	—	—		—	—		—		(14)		—		—		(14)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—	—		—		—		74		—		74
Changes in equity attributable to noncontrolling interests	—	—		—	—		—		—		—		2		2
Share-based compensation	—	—		—	—		21		—		—		—		21
Balances as of September 30, 2024	457	$	5	—	$	(25)	$	6,551	$	2,558	$	(771)	$	18	$	8,335



	Common stock
(In millions)	Shares	Amount		Additional paid-in capital		Retained earnings		Net parent investment		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of June 30, 2023	455	$	5	$	6,451	$	576	$	—	$	70	$	12	$	7,114
Issuance of shares under equity awards, net of shares withheld for taxes and other	—	—		(11)		—		—		—		—		(11)
Net income attributable to GE HealthCare	—	—		—		375		—		—		—		375
Dividends declared ($0.03 per common share)	—	—		—		(14)		—		—		—		(14)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—		—		—		(350)		—		(350)
Changes in equity attributable to noncontrolling interests	—	—		—		—		—		—		(1)		(1)
Share-based compensation	—	—		29		—		—		—		—		29
Balances as of September 30, 2023	455	$	5	$	6,469	$	937	$	—	$	(280)	$	11	$	7,142

The accompanying notes are an integral part of these condensed consolidated financial statements.



	Common stock			Treasury stock
(In millions)	Shares	Amount		Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of December 31, 2023	455	$	5	—	$	—	$	6,493	$	1,326	$	(691)	$	12	$	7,145











Issuance of shares under equity awards, net of shares withheld for taxes and other	2	—		—	(25)		(34)		—		—		—		(59)
Net income attributable to GE HealthCare	—	—		—	—		—		1,272		—		—		1,272
Dividends declared ($0.09 per common share)	—	—		—	—		—		(41)		—		—		(41)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—	—		—		—		(80)		—		(80)
Changes in equity attributable to noncontrolling interests	—	—		—	—		—		—		—		6		6
Share-based compensation	—	—		—	—		92		—		—		—		92
Balances as of September 30, 2024	457	$	5	—	$	(25)	$	6,551	$	2,558	$	(771)	$	18	$	8,335



	Common stock
(In millions)	Shares	Amount		Additional paid-in capital		Retained earnings		Net parent investment		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of December 31, 2022	—	$	—	$	—	$	—	$	11,235	$	(1,878)	$	5	$	9,362
Net transfers from GE, including Spin-Off-related adjustments	—	—		—		—		(4,842)		2,000		2		(2,840)
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	454	5		6,388		—		(6,393)		—		—		—
Issuance of shares under equity awards, net of shares withheld for taxes and other	1	—		—		—		—		—		—		—
Net income attributable to GE HealthCare	—	—		—		1,165		—		—		—		1,165
Dividends declared ($0.09 per common share)	—	—		—		(41)		—		—		—		(41)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—		—		—		(402)		—		(402)
Changes in equity attributable to noncontrolling interests	—	—		—		—		—		—		4		4
Share-based compensation	—	—		81		—		—		—		—		81
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	—	—		—		(187)		—		—		—		(187)
Balances as of September 30, 2023	455	$	5	$	6,469	$	937	$	—	$	(280)	$	11	$	7,142

The accompanying notes are an integral part of these condensed consolidated financial statements.


Condensed Consolidated Statements of Cash Flows (Unaudited)
	For the nine months ended September 30
(In millions)	2024		2023
Net income	$	1,312	$	1,198
Less: Income (loss) from discontinued operations, net of taxes	—		(4)
Net income from continuing operations	$	1,312	$	1,202
Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities
Depreciation of property, plant, and equipment	203		188
Amortization of intangible assets	237		278

Gain on fair value remeasurement of contingent consideration	(19)		(17)
Net periodic postretirement benefit plan (income) expense	(271)		(291)
Postretirement plan contributions	(257)		(259)
Share-based compensation	92		81
Provision for income taxes	435		550
Cash paid during the year for income taxes	(375)		(375)


Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables	83		(82)
Due from related parties	24		9
Inventories	(157)		(85)
Contract and other deferred assets	(33)		(75)
Accounts payable	3		(93)
Due to related parties	(72)		(87)
Contract liabilities	(25)		69
Current compensation and benefits	(97)		37
All other operating activities - net	(41)		1
Cash from (used for) operating activities – continuing operations	1,042		1,051
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(299)		(293)
Dispositions of property, plant, and equipment	—		1
Purchases of businesses, net of cash acquired	(259)		(147)
Purchases of investments	(33)		(21)
All other investing activities - net	(83)		(10)
Cash from (used for) investing activities – continuing operations	(674)		(470)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	—		(9)
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	994		2,020
Repayments and other reductions (maturities longer than 90 days)	(162)		(9)
Dividends paid to stockholders	(41)		(28)
Redemption of noncontrolling interests	—		(211)
Net transfers (to) from GE	—		(1,317)
Proceeds from stock issued under employee benefit plans	31		31
Taxes paid related to net share settlement of equity awards	(90)		(31)
All other financing activities - net	(28)		(24)
Cash from (used for) financing activities – continuing operations	704		422
Cash from (used for) operating activities – discontinued operations	(4)		—


Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(2)		(34)
Increase (decrease) in cash, cash equivalents, and restricted cash	1,066		969
Cash, cash equivalents, and restricted cash at beginning of year	2,506		1,451

Cash, cash equivalents, and restricted cash as of September 30	$	3,572	$	2,420

Supplemental disclosure of cash flows information
Cash paid during the year for interest	$	(339)	$	(318)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$	72	$	80

The accompanying notes are an integral part of these condensed consolidated financial statements.

NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, helping enable precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring.

On January 3, 2023, the General Electric Company, which now operates as GE Aerospace (“GE”), completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE’s common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. On April 2, 2024, GE completed the separation of its GE Vernova business into an independent publicly traded company. As of September 30, 2024, GE’s beneficial ownership was approximately 2.9% of the Company’s outstanding common stock.

In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility, and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,840 million. These items substantially consisted of the transfer of: (1) certain pension plan liabilities and assets, (2) certain deferred income taxes, (3) deferred compensation liabilities, and (4) employee termination obligations.

In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 17, “Related Parties and Transition Services Agreement” for more information on these agreements and related transactions.

The condensed consolidated financial statements (the “financial statements”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three and nine months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2023 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation, which provides additional detail to readers of the financial statements. Amounts related to current compensation and benefit obligations that were previously reported within the All other current liabilities and All other operating activities lines on the Condensed Consolidated Statements of Financial Position and Statements of Cash Flows, respectively, have been reclassified to separate lines on the respective financial statements. Additionally on the Condensed Consolidated Statements of Cash Flows, amounts related to purchase of investments previously reported within All other investing activities, and amounts related to equity award activity previously reported within All other financing activities, have been reclassified to separate lines.

Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”). Following this realignment, the Company continues to have four reportable segments: Imaging, AVS, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure. See Note 3, “Segment Information” for more information.

The financial statements and notes should be read in conjunction with the Company’s audited consolidated and combined financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

ESTIMATES AND ASSUMPTIONS.

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.

RECENT ACCOUNTING PRONOUNCEMENTS.

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect that ASU 2023-07 will have on our financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect that ASU 2023-09 will have on our financial statement disclosures.

NOTE 2. REVENUE RECOGNITION

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as on-demand service parts, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services.

CONTRACT ASSETS.

Contract assets reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.


Contract and Other Deferred Assets	As of
	September 30, 2024		December 31, 2023
Contract assets	$	685	$	600
Other deferred assets	361		400
Contract and other deferred assets	1,046		1,000
Non-current contract assets(1)	93		72
Non-current other deferred assets(1)	96		96
Total contract and other deferred assets	$	1,235	$	1,168

(1)Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

CONTRACT LIABILITIES.

Contract liabilities include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations (“RPO”) are expected to be satisfied with our customers.

As of September 30, 2024 and December 31, 2023, contract liabilities were approximately $2,619 million and $2,623 million, respectively, of which the non-current portion of $704 million and $705 million, respectively, was recognized in All other non-current liabilities in the Condensed Consolidated Statements of Financial Position. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,381 million and $1,357 million for the nine months ended September 30, 2024 and 2023, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

RPO represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty. As of September 30, 2024, the aggregate amount of the contracted revenues allocated to our unsatisfied performance obligations was $14,563 million. We expect to recognize revenue as we satisfy our RPO as follows: (1) product-related RPO of $4,808 million of which 98% is expected to be recognized within two years, and the remaining thereafter; and (2) services-related RPO of $9,756 million of which 64% and 91% are expected to be recognized within two years and five years, respectively, and the remaining thereafter.

NOTE 3. SEGMENT INFORMATION

Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions. The AVS segment has a portfolio that serves customers across two core areas: Specialized Ultrasound and Procedural Guidance. Specialized Ultrasound includes Radiology, Primary Care and Point of Care, and Women’s Health Ultrasound. Procedural Guidance includes Cardiovascular and Interventional Solutions, and Surgical Innovations. Under the new structure, IGT is reported within the Procedural Guidance business in AVS. Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure.

Following this realignment, the Company continues to have four reportable segments: Imaging, AVS, PCS, and PDx. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments.

The performance of these segments was principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss).


Total Revenues by Segment	For the three months ended September 30				For the nine months ended September 30
	2024		2023		2024		2023
Total Imaging	$	2,229	$	2,236	$	6,462	$	6,552
AVS:
Procedural Guidance	647		641		1,967		1,938
Specialized Ultrasound	569		573		1,725		1,774
Total AVS	1,216		1,214		3,692		3,712
PCS:
Monitoring Solutions	556		573		1,621		1,688
Life Support Solutions	223		191		677		627
Total PCS	779		764		2,298		2,315
Total PDx	625		589		1,862		1,715
Other(1)	15		19		39		52
Total revenues	$	4,863	$	4,822	$	14,353	$	14,346

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services (“HFS”) which does not meet the definition of an operating segment.


Segment EBIT	For the three months ended September 30				For the nine months ended September 30
	2024		2023		2024		2023
Segment EBIT
Imaging	$	287	$	243	$	660	$	566
AVS	232		254		744		798
PCS	82		80		241		273
PDx	193		166		571		473
Other(1)	1		1		2		9
	795		744		2,217		2,119
Restructuring costs	(22)		(3)		(90)		(34)
Acquisition and disposition-related benefits (charges)	4		14		7		15
Gain (loss) on business and asset dispositions	(1)		—		—		—
Spin-Off and separation costs	(56)		(45)		(182)		(175)
Amortization of acquisition-related intangible assets	(34)		(32)		(100)		(95)
Investment revaluation gain (loss)	(1)		2		(26)		1
Interest and other financial charges – net	(130)		(138)		(383)		(411)
Non-operating benefit income (costs)	102		94		306		332
Income before income taxes	$	658	$	636	$	1,747	$	1,752

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.

NOTE 4. RECEIVABLES


Current Receivables	As of
	September 30, 2024		December 31, 2023
Current customer receivables(1)	$	3,265	$	3,339
Non-income based tax receivables	139		166
Other sundry receivables	119		118
Current sundry receivables	257		284
Allowance for credit losses	(104)		(98)
Total current receivables – net	$	3,418	$	3,525

(1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $135 million and $144 million as of September 30, 2024 and December 31, 2023, respectively.


Long-Term Receivables	As of
	September 30, 2024		December 31, 2023
Long-term customer receivables	$	72	$	55
Non-income based tax receivables	23		26
Other sundry receivables	102		73
Long-term sundry receivables	125		99

Allowance for credit losses	(30)		(30)
Total long-term receivables – net(1)	$	167	$	124

(1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

NOTE 5. FINANCING RECEIVABLES



	As of
	September 30, 2024		December 31, 2023
Loans receivable, at amortized cost	$	23	$	29
Investment in financing leases, net of deferred income	74		71
Allowance for credit losses	(3)		(3)
Current financing receivables – net(1)	94		97
Loans receivable, at amortized cost	32		37
Investment in financing leases, net of deferred income	151		146
Allowance for credit losses	(5)		(5)
Non-current financing receivables – net(1)	$	178	$	178

(1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.

As of September 30, 2024, 4%, 4%, and 4% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2023, 5%, 5%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

NOTE 6. LEASES

Operating lease liabilities recognized within All other current liabilities and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position were $378 million and $383 million as of September 30, 2024 and December 31, 2023, respectively. The total lease expense related to our operating lease portfolio was $70 million and $54 million for the three months ended September 30, 2024 and 2023, respectively, and $189 million and $167 million for the nine months ended September 30, 2024 and 2023, respectively.

NOTE 7. ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

MIM Software

On April 1, 2024, the Company acquired 100% of the stock of MIM Software Inc. (“MIM Software”) for approximately $259 million, net of cash acquired, $13 million of potential earn-out payments, and up to $23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $195 million, customer-related intangible assets of $52 million, developed technology intangible assets of $48 million, net deferred tax liabilities of $19 million, and other net assets of $7 million. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide.

Revenue and earnings of MIM Software included in the Company’s financial statements since the acquisition date are not material to our consolidated revenue and earnings. If the acquisition of MIM Software had taken place as of the beginning of 2023, consolidated revenues and earnings would not have been significantly different from reported amounts.

Caption Health

On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million of future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users.

GOODWILL.

As discussed in Note 3, “Segment Information”, effective in the third quarter of 2024, the Company (1) reorganized its operations and moved responsibility for and reporting of IGT from the Imaging segment to the Ultrasound Segment and (2) renamed the Ultrasound segment the AVS segment. This resulted in a $1,031 million increase in the Company’s allocation of goodwill to its AVS segment and a corresponding decrease in the goodwill allocated to the Imaging segment. The Company allocated goodwill to its new reporting units using a relative fair value approach.


	Imaging		AVS		PCS		PDx		Total
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936
Reallocation	(1,031)		1,031		—		—		—
Acquisitions	195		—		—		—		195
Foreign currency exchange and other	2		3		1		—		6
Balance at September 30, 2024	$	3,598	$	4,967	$	2,039	$	2,534	$	13,138

We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. In connection with the change in reportable segments in the third quarter of 2024, the Company evaluated the goodwill of our Imaging and AVS reporting units for impairment before and after the segment realignment. There were no impairments identified as part of these assessments. In addition, with respect to the PCS and PDx reporting units, we did not identify any events or circumstances that required an interim impairment test since the last annual impairment testing date.

OTHER INTANGIBLE ASSETS.

Intangible assets decreased during the nine months ended September 30, 2024, primarily as a result of amortization, partially offset by additions related to the acquisition of MIM Software. Substantially all of our intangible assets are subject to amortization. Amortization expense was $77 million and $89 million for the three months ended September 30, 2024 and 2023, respectively, and $237 million and $278 million for the nine months ended September 30, 2024 and 2023, respectively.

NOTE 8. BORROWINGS

The Company’s borrowings include the following senior unsecured notes and credit agreements:

Senior Unsecured Notes

The Company’s borrowings include $9,250 million aggregate principal amount of senior unsecured notes in seven series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). This includes $1,000 million aggregate principal amount of 4.800% senior unsecured notes due in 2029 issued by the Company in the third quarter of 2024. Refer to the table below for further information about the Notes.

Credit Facilities

The Company has credit agreements providing for:

a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million, maturing on January 3, 2028;
a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million, maturing on December 11, 2024; and
a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million, maturing on January 2, 2026 (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”).

There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $1,000 million and $1,150 million outstanding on the Term Loan Facility as of September 30, 2024 and December 31, 2023, respectively.

In the first quarter of 2024, we repaid $150 million of the Term Loan Facility and had no principal debt repayments on the Notes in the nine months ended September 30, 2024.


Borrowings Composition	As of
	September 30, 2024		December 31, 2023
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
4.800% senior notes due August 14, 2029	1,000		—
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	1,000		1,150
Other	42		52
Total principal debt issued	10,292		9,452
Less: Unamortized debt issuance costs and discounts	36		35
Add: Cumulative basis adjustment for fair value hedges	57		25
Total borrowings	10,312		9,442
Less: Short-term borrowings(1)	1,007		1,006
Long-term borrowings	$	9,306	$	8,436

(1) Short-term borrowings as of September 30, 2024 and December 31, 2023 includes $1,004 million and $1,002 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts.

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

As of September 30, 2024 and December 31, 2023, the Company had bank guarantees and surety bonds of approximately $801 million and $751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $28 million and $39 million of guarantees as of September 30, 2024 and December 31, 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated Statements of Financial Position reflect a liability of $3 million and $4 million as of September 30, 2024 and December 31, 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 13, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

NOTE 9. POSTRETIREMENT BENEFIT PLANS

We sponsor a number of pension and retiree health and life insurance benefit plans that we present in three categories: Principal Pension Plans, Other Pension Plans, and Other Postretirement Plans (“OPEB Plans”). Please refer to Note 10, “Postretirement Benefit Plans” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for further information. On January 1, 2024, we transitioned from legacy GE multiple-employer OPEB plans to GE HealthCare sponsored single-employer OPEB plans. This change did not have an impact on our results of operations or financial position. Pension plans with pension assets or obligations less than $50 million are not included in the results below.


Components of Expense (Income)	For the three months ended September 30
	Principal Pension Plans				Other Pension Plans				OPEB

	2024		2023		2024		2023		2024		2023
Service cost – Operating	$	7	$	8	$	6	$	6	$	2	$	2
Interest cost	227		237		50		53		14		15
Expected return on plan assets	(284)		(292)		(64)		(65)		—		—
Amortization of net loss (gain)	(19)		(30)		5		2		(15)		(16)
Amortization of prior service cost (credit)	2		1		—		(1)		(22)		(22)
Curtailment loss (gain)	—		17		—		—		—		—
Non-operating	$	(74)	$	(67)	$	(9)	$	(11)	$	(23)	$	(23)
Net periodic expense (income)	$	(67)	$	(58)	$	(3)	$	(5)	$	(21)	$	(21)



	For the nine months ended September 30
	Principal Pension Plans				Other Pension Plans					OPEB Plans

	2024		2023			2024		2023			2024		2023
Service cost – Operating	$	21	$	25		$	18	$	18		$	6	$	6
Interest cost	681		715			150		157			41		45
Expected return on plan assets	(851)		(878)			(190)		(192)			—		—
Amortization of net loss (gain)	(57)		(96)			15		7			(45)		(48)
Amortization of prior service cost (credit)	6		2			—		(3)			(66)		(66)
Curtailment loss (gain)	—		17			—		—			—		—

Non-operating	$	(221)	$	(240)		$	(25)	$	(31)		$	(70)	$	(69)
Net periodic expense (income)	$	(200)	$	(215)		$	(7)	$	(13)		$	(64)	$	(63)

In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees will be frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $17 million as non-operating benefit costs.

In the nine months ended September 30, 2024, the Company made cash benefit payments totaling $91 million to its Principal Pension Plans, $67 million to its Other Pension Plans, and $99 million to its OPEB Plans. In 2024, the Company expects to make total cash contributions of approximately $336 million to these plans. The Company does not have a required minimum funding contribution for its U.S.-based GE HealthCare Pension Plan in 2024. Future contributions will depend on capital market conditions, including equity market returns, and other factors.

Defined Contribution Plan

GE HealthCare sponsors a defined contribution plan for its eligible U.S. employees. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan were $27 million and $28 million for the three months ended September 30, 2024 and 2023, respectively, and $100 million and $94 million for the nine months ended September 30, 2024 and 2023, respectively.

NOTE 10. INCOME TAXES

Our effective income tax rate was 25.5% and 39.3% for the three months ended September 30, 2024 and 2023, respectively, and 24.9% and 31.4% for the nine months ended September 30, 2024 and 2023, respectively. The tax rate for the three and nine months ended September 30, 2024 is higher than the U.S. statutory rate primarily due to the tax cost of global activities, reconciling adjustments to recorded tax account balances associated with the Spin-Off, withholding taxes, and state taxes, partially offset by research and development benefits.

The effective tax rate for 2023 is higher than the U.S. statutory rate primarily due to the tax cost of global activities, including the U.S. taxation on international operations, tax effect of foreign currency movement, withholding taxes, and state taxes. Benefit (provision) for income taxes for the three and nine months ended September 30, 2023 included $105 million of deferred tax provision associated with the Tax Matters Agreement (“TMA”) with GE including the effect of completing the 2022 GE U.S. federal tax return. In addition, Other (income) expense – net for the three and nine months ended September 30, 2023 included a $30 million benefit related to changes in tax indemnities with GE also associated with the TMA and the effect of completing the 2022 GE U.S. federal tax return.

Post Spin-Off, the Company’s previously undistributed earnings of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in the first quarter of 2023, an incremental deferred tax liability of $30 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings.

The Company is currently being audited in a number of jurisdictions for tax years 2004-2022, including China, Germany, Norway, the United Kingdom, and the United States.

NOTE 11. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, were as follows.


	For the three months ended September 30, 2024
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
June 30, 2024	$	(1,812)	$	961	$	6	$	(845)
Other comprehensive income (loss) before reclassifications – net of taxes of $27, $8, and $10	177		(29)		(34)		114
Reclassifications from AOCI – net of taxes(2) of $—, $12, and $1	—		(38)		(3)		(41)
Other comprehensive income (loss)	177		(67)		(36)		74


Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
September 30, 2024	$	(1,635)	$	894	$	(30)	$	(771)


	For the three months ended September 30, 2023
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
June 30, 2023	$	(1,757)	$	1,847	$	(20)	$	70
Other comprehensive income (loss) before reclassifications – net of taxes of $(16), $69, and $(6)	(143)		(214)		18		(339)

Reclassifications from AOCI – net of taxes(2) of $—, $16, and $(1)	—		(50)		4		(46)
Other comprehensive income (loss)	(143)		(264)		22		(385)

Less: Other comprehensive income (loss) attributable to noncontrolling interests	(35)		—		—		(35)
September 30, 2023	$	(1,865)	$	1,583	$	2	$	(280)


	For the nine months ended September 30, 2024
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2023	$	(1,706)	$	1,033	$	(18)	$	(691)
Other comprehensive income (loss) before reclassifications – net of taxes of $13, $7, and $3	70		(27)		(10)		33
Reclassifications from AOCI – net of taxes(2) of $—, $33, and $1	—		(111)		(3)		(114)
Other comprehensive income (loss)	70		(138)		(12)		(80)


Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
September 30, 2024	$	(1,635)	$	894	$	(30)	$	(771)


	For the nine months ended September 30, 2023
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclassifications – net of taxes of $1, $60, and $(4)	(84)		(190)		10		(264)

Reclassifications from AOCI – net of taxes(2) of $—, $49, and $5	—		(156)		(17)		(173)
Other comprehensive income (loss)	(84)		(346)		(7)		(437)
Spin-Off related adjustments – net of taxes of $—, $(509), and $—	28		1,972		—		2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(36)		1		—		(35)
September 30, 2023	$	(1,865)	$	1,583	$	2	$	(280)

(1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) during the three and nine months ended September 30, 2024 and 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, and equity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes.

Cash Flow Hedges

For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of September 30, 2024, we expect to reclassify $35 million of pre-tax net deferred loss associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions.

The cash flows associated with derivatives designated as cash flow hedges are recorded in All other operating activities in the Condensed Consolidated Statements of Cash Flows.

Net Investment Hedges

We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. As of September 30, 2024, these contracts were designated as hedges of our net investment in foreign operations, primarily in Euro and Chinese Renminbi currencies.

The cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities in the Condensed Consolidated Statements of Cash Flows. For the nine months ended September 30, 2024, All other investing activities includes a $94 million payment for the settlement of cross-currency swaps that were designated in net investment hedges. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities in the Condensed Consolidated Statements of Cash Flows.

Fair Value Hedges

We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges to hedge the changes in fair value due to benchmark interest rate risk of specific designated cash flows of our senior unsecured notes.

We record the changes in fair value on these swap contracts in Interest and other financial charges – net in our Condensed Consolidated Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment.

Cash flows for the periodic interest settlements on the interest rate swaps are recorded in All other operating activities in the Condensed Consolidated Statements of Cash Flows.

Derivatives Not Designated as Hedging Instruments

We also execute derivative instruments, such as foreign currency forward contracts and equity-linked total return swaps, which are not designated as qualifying hedges. These derivatives serve as economic hedges of foreign currency exchange rate and equity price risks. We also identify and record foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of any substantive party to the contract and record them as embedded derivatives.

The changes in fair value of derivatives not designated in qualifying hedge transactions are recorded in Cost of products, Cost of services, Selling, general, and administrative (“SG&A”), and Other (income) expense – net in the Condensed Consolidated Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Condensed Consolidated Statements of Income.

The cash flows associated with derivatives not designated but used as economic hedges are recorded, based on the nature of the underlying hedged transaction, in All other operating activities and All other investing activities in the Condensed Consolidated Statements of Cash Flows. The cash flows related to embedded derivatives are included in All other operating activities in the Condensed Consolidated Statements of Cash Flows.

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	September 30, 2024						December 31, 2023
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,504	$	2	$	42	$	1,356	$	8	$	30
Derivatives accounted for as cash flow hedges	1,504		2		42		1,356		8		30
Cross-currency swaps(1)	2,148		18		174		2,209		—		204
Foreign currency forward and options contracts	1,625		17		20		991		9		11
Derivatives accounted for as net investment hedges	3,773		35		195		3,200		9		215
Interest rate swaps(1)	1,700		61		5		1,000		35		10
Derivatives accounted for as fair value hedges	1,700		61		5		1,000		35		10
Foreign currency forward contracts	3,854		33		13		3,597		19		12
Other derivatives(1)(2)	397		37		3		438		57		2



Derivatives not designated as hedging instruments	4,251		70		16		4,035		76		14
Total derivatives	$	11,229	$	168	$	257	$	9,591	$	128	$	269

(1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position.

(2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts. As of December 31, 2023, Other derivatives also included commodity contracts.

The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges.


	September 30, 2024				December 31, 2023
	Carrying amount		Cumulative basis adjustment included in the carrying amount		Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated in fair value hedges	$	1,753	$	57	$	1,023	$	25

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis in our Condensed Consolidated Statements of Financial Position and in the table above.

As of September 30, 2024 and December 31, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $85 million and $41 million, respectively.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the three months ended September 30				For the nine months ended September 30
	2024		2023		2024		2023
Cash flow hedges	$	(43)	$	24	$	(13)	$	14
Net investment hedges(1)	(116)		64		(57)		(7)

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income.


Derivative Financial Instruments and Hedging Activity	For the three months ended September 30, 2024
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	3	$	1	$	—	$	—	$	—
Effects of cash flow hedges	3		1		—		—		—
Cross-currency swaps	—		—		—		7		—
Foreign currency forward and options contracts	—		—		—		4		—
Effects of net investment hedges(1)	—		—		—		11		—

Interest rate swaps(2)	—		—		—		76		—
Debt basis adjustment on Long-term borrowings	—		—		—		(84)		—

Effects of fair value hedges	—		—		—		(7)		—
Foreign currency forward contracts	28		7		—		—		—



Other derivatives(3)	—		—		2		—		5
Effects of derivatives not designated as hedging instruments	28		7		2		—		5























	For the three months ended September 30, 2023
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(5)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(5)		(1)		—		—		—
Cross-currency swaps	—		—		—		8		—
Foreign currency forward and option contracts	—		—		—		1		1
Effects of net investment hedges(1)	—		—		—		9		1

Interest rate swaps	—		—		—		—		—
Debt basis adjustment on Long-term borrowings	—		—		—		—		—

Effects of fair value hedges	—		—		—		—		—
Foreign currency forward contracts	(38)		(9)		—		—		4
Other derivatives(3)	—		—		(2)		—		10
Effects of derivatives not designated as hedging instruments	(38)		(9)		(2)		—		14


	For the nine months ended September 30, 2024
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	3	$	1	$	—	$	—	$	—
Effects of cash flow hedges	3		1		—		—		—
Cross-currency swaps	—		—		—		24		—
Foreign currency forward and options contracts	—		—		—		8		—
Effects of net investment hedges(1)	—		—		—		32		—

Interest rate swaps(2)	—		—		—		11		—
Debt basis adjustment on Long-term borrowings	—		—		—		(31)		—

Effects of fair value hedges	—		—		—		(21)		—
Foreign currency forward contracts	21		5		—		—		—



Other derivatives(3)	—		—		7		—		28
Effects of derivatives not designated as hedging instruments	21		5		7		—		28























	For the nine months ended September 30, 2023
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	18	$	4	$	—	$	—	$	—
Effects of cash flow hedges	18		4		—		—		—
Cross-currency swaps	—		—		—		25		—
Foreign currency forward and option contracts	—		—		—		1		1
Effects of net investment hedges(1)	—		—		—		26		1

Interest rate swaps	—		—		—		—		—
Debt basis adjustment on Long-term borrowings	—		—		—		—		—

Effects of fair value hedges	—		—		—		—		—
Foreign currency forward contracts	(28)		(6)		—		—		10
Other derivatives(3)	—		—		5		—		36
Effects of derivatives not designated as hedging instruments	(28)		(6)		5		—		46

(1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three and nine months ended September 30, 2024 and 2023.

(2) Amount includes $(7) million and $(21) million of interest expense on interest rate derivatives for the three and nine months ended September 30, 2024, respectively.

(3) Other derivatives are primarily comprised of embedded derivatives and derivatives related to equity contracts.

(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income.

FAIR VALUE MEASUREMENTS.

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of September 30, 2024								As of December 31, 2023
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	—	$	231	$	—	$	231	$	—	$	200	$	—	$	200
Investment securities	26		—		—		26		31		—		—		31
Derivatives	—		168		—		168		—		128		—		128
Liabilities:
Derivatives	—		257		—		257		—		269		—		269
Contingent consideration	—		—		35		35		—		—		44		44

Cash equivalents

As of September 30, 2024 and December 31, 2023, Cash, cash equivalents, and restricted cash of $3,568 million and $2,504 million, respectively, included money market funds of $231 million and $200 million, and other cash equivalents of $2,303 million and $1,023 million, respectively. The carrying values of the other cash equivalents approximates the fair value due to their short maturities and are valued using Level 1 or Level 2 inputs. Refer to Note 16, “Supplemental Financial Information” for further information.

Derivatives

Derivatives are measured at fair value using a discounted cash flow method or option models using interest rates, foreign exchange spot and forward rates and yield curves observable at commonly quoted intervals, implied volatilities, and credit spreads as key inputs. Unobservable inputs relate to our own credit risk which is not significant to the overall measurement of fair value.

Contingent consideration

Contingent consideration is recorded at fair value based on estimates of future cash flows in connection with business acquisitions. As the valuation of these liabilities is based on inputs that are less observable or not observable in the market, the determination of fair value is classified within Level 3 of the fair value hierarchy.

Non-recurring fair value measurements

Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the nine months ended September 30, 2024 and 2023.

Fair value of other financial instruments

The estimated fair value of borrowings as of September 30, 2024 and December 31, 2023 was $10,937 million and $9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $10,312 million and $9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” and Note 16, “Supplemental Financial Information” for further information.

NOTE 13. COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information.

Following the Spin-Off, which was completed pursuant to the Separation and Distribution Agreement, the Company had remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE was obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could have been obligated to make payments under the applicable instruments for which GE was obligated to reimburse and indemnify the Company. As of December 31, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, was approximately $114 million. In the second quarter of 2024, these remaining performance guarantees were all terminated or replaced.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.



	For the nine months ended September 30
	2024		2023
Balance at beginning of period	$	192	$	193
Current-year provisions	143		158
Expenditures	(166)		(159)
Other changes	(1)		(3)
Balance at end of period	$	168	$	189

Product warranties are recognized within All other current liabilities in the Condensed Consolidated Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matters described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matters described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On June 24, 2024, the Supreme Court vacated the D.C. Circuit’s decision and remanded the case to the D.C. Circuit for further consideration in light of Twitter, Inc. v. Taamneh, a separate case decided by the Supreme Court in May 2023. The proceedings in the District Court are currently inactive.

Government Disclosures

From time to time, we make self-disclosures regarding our compliance with the Foreign Corrupt Practices Act (“FCPA”) and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us. We, with the assistance of outside counsel, made voluntary self-disclosures to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) beginning in 2018 regarding tender irregularities and other potential violations of the FCPA relating to our activities in certain provinces in China. We have been engaged in ongoing discussions with each of the SEC and the DOJ regarding these matters. We are fully cooperating with the reviews by these agencies and have implemented, and continue to implement, enhancements to our compliance policies and practices. At this time, we are unable to predict the duration, scope, result, or related costs associated with these disclosures to the SEC and the DOJ. We also are unable to predict what, if any, action may be taken by the SEC or the DOJ or what penalties or remedial actions they may seek. Any determination that our operations or activities are not in compliance with existing laws or regulations, including applicable foreign laws, could result in the imposition of fines, penalties, disgorgement, equitable relief, or other losses.

NOTE 14. RESTRUCTURING ACTIVITIES

Restructuring activities are essential to optimize the business operating model for GE HealthCare and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring activities are not allocated.

Net expenses for restructuring initiatives committed to by management through September 30, 2024 are included in the table below.


Restructuring Activities	For the three months ended September 30				For the nine months ended September 30
	2024		2023		2024		2023
Employee termination costs	$	19	$	1	$	61	$	26
Facility and other exit costs	2		1		15		2
Asset write-downs	1		1		14		6
Total restructuring activities – net	$	22	$	3	$	90	$	34

These restructuring initiatives are expected to result in additional expenses of approximately $21 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Condensed Consolidated Statements of Income.

Liabilities related to restructuring are recognized within Current compensation and benefits, All other current liabilities, Non-current compensation and benefits, and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position and totaled $80 million and $68 million as of September 30, 2024 and December 31, 2023, respectively.

NOTE 15. EARNINGS PER SHARE

The numerator for both basic and diluted earnings per share (“EPS”) is Net income attributable to GE HealthCare common stockholders. The denominator of basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units, and performance share units is reflected in the denominator for diluted EPS using the treasury stock method.


Earnings Per Share	For the three months ended September 30				For the nine months ended September 30
(In millions, except per share amounts)	2024		2023		2024		2023
Numerator:
Net income from continuing operations	$	490	$	386	$	1,312	$	1,202
Net (income) loss attributable to noncontrolling interests	(19)		(7)		(40)		(33)
Net income from continuing operations attributable to GE HealthCare	470		379		1,272		1,169
Deemed preferred stock dividend of redeemable noncontrolling interest	—		—		—		(183)
Net income from continuing operations attributable to GE HealthCare common stockholders	470		379		1,272		986
Income (loss) from discontinued operations, net of taxes	—		(4)		—		(4)
Net income attributable to GE HealthCare common stockholders	$	470	$	375	$	1,272	$	982
Denominator:
Basic weighted-average shares outstanding	457		455		456		455
Dilutive effect of common stock equivalents	2		3		2		3
Diluted weighted-average shares outstanding	459		458		459		458
Basic Earnings Per Share:
Continuing operations	$	1.03	$	0.83	$	2.79	$	2.17
Discontinued operations	—		(0.01)		—		(0.01)
Attributable to GE HealthCare common stockholders	1.03		0.82		2.79		2.16
Diluted Earnings Per Share:
Continuing operations	$	1.02	$	0.83	$	2.77	$	2.16
Discontinued operations	—		(0.01)		—		(0.01)
Attributable to GE HealthCare common stockholders	1.02		0.82		2.77		2.15
Antidilutive securities(1)	2		4		4		4

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

NOTE 16. SUPPLEMENTAL FINANCIAL INFORMATION


Cash, Cash Equivalents, and Restricted Cash	As of
	September 30, 2024		December 31, 2023
Cash and cash equivalents(1)	$	3,550	$	2,494
Short-term restricted cash	18		10
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	3,568		2,504
Long-term restricted cash(2)	4		2
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$	3,572	$	2,506

(1) The increase in cash and cash equivalents was primarily due to proceeds from the issuance of senior unsecured notes by the Company in the third quarter of 2024. Refer to Note 8, “Borrowings” for further information.

(2) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.


Inventories	As of
	September 30, 2024		December 31, 2023
Raw materials	$	992	$	961
Work in process	100		91
Finished goods	1,032		908
Inventories(1)	$	2,124	$	1,960

(1) Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.


Property, Plant, and Equipment – Net	As of
	September 30, 2024		December 31, 2023
Original cost	$	5,356	$	5,208
Accumulated depreciation	(3,176)		(3,064)
Right-of-use operating lease assets, net of amortization	359		356
Property, plant, and equipment – net	$	2,539	$	2,500


All Other Current and Non-Current Assets	As of
	September 30, 2024		December 31, 2023
Prepaid expenses and deferred costs	$	197	$	147
Financing receivables – net	94		97
Derivative instruments	114		84
Other(1)	72		61
All other current assets	$	476	$	389
Prepaid pension asset	$	797	$	716
Equity method and other investments	361		357
Financing receivables – net	178		178
Long-term receivables – net	167		124
Inventories	151		147
Contract and other deferred assets	189		168
Other(2)	255		191
All other non-current assets	$	2,098	$	1,881

(1) Current Other primarily consists of tax receivables.

(2) Non-current Other primarily consists of derivative instruments, indemnity assets associated with separation agreements with GE, capitalized costs associated with cloud computing arrangements, and tax receivables.


All Other Current and Non-Current Liabilities	As of
	September 30, 2024		December 31, 2023
Sales allowances and related liabilities	$	215	$	228
Income and indirect tax liabilities including uncertain tax positions	160		260
Product warranties	168		192
Accrued freight and utilities	127		132
Operating lease liabilities	114		110
Derivative instruments(1)	84		128
Interest payable on borrowings	164		87
Environmental and asset retirement obligations	19		21
Other(2)	356		335
All other current liabilities	$	1,409	$	1,493
Contract liabilities	$	704	$	705
Operating lease liabilities	263		273
Environmental and asset retirement obligations	306		265
Income and indirect tax liabilities including uncertain tax positions	205		208
Derivative instruments	183		136
Finance lease obligations	43		38
Sales allowances and related liabilities	23		27
Other(3)	195		225
All other non-current liabilities	$	1,920	$	1,877

(1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information.

(2) Current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and dividends payable to stockholders.

(3) Non-current Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.

SUPPLY CHAIN FINANCE PROGRAMS.

The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements.

Included within Accounts payable in the Condensed Consolidated Statements of Financial Position as of September 30, 2024 and December 31, 2023 were $403 million and $365 million, respectively, of confirmed supplier invoices that are outstanding and subject to third-party programs.

REDEEMABLE NONCONTROLLING INTERESTS**.**

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value.

The activity attributable to redeemable noncontrolling interests for the nine months ended September 30, 2024 and 2023 is presented below.


Redeemable Noncontrolling Interests	For the nine months ended September 30
	2024		2023
Balance at beginning of period	$	165	$	230
Net income attributable to redeemable noncontrolling interests	35		28
Redemption value adjustments(1)	—		183
Distributions to and exercise of redeemable noncontrolling interests and other(2)	(23)		(280)
Balance at end of period	$	177	$	161

(1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to Retained earnings in the Condensed Consolidated Statements of Financial Position.

(2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023.


Other Income (Expense) – Net	For the three months ended September 30				For the nine months ended September 30
	2024		2023		2024		2023
Net financing income and investment income (loss)	$	5	$	6	$	(11)	$	19
Equity method income (loss)	2		—		5		9
Change in fair value of assumed obligations	(9)		(5)		(26)		(24)
Other items, net(1)	11		62		33		81
Total other income (expense) – net	$	9	$	63	$	1	$	85

(1) Other items, net primarily consists of government grants, lease income, gains and losses related to derivatives, and licensing and royalty income for the three and nine months ended September 30, 2024, and change in tax indemnity, gains and losses related to derivatives, licensing and royalty income, and lease income for the three and nine months ended September 30, 2023.

NOTE 17. RELATED PARTIES AND TRANSITION SERVICES AGREEMENT

In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including the Transition Services Agreement (“TSA”). These agreements were structured in anticipation of GE’s transaction to separate the GE Vernova business as described in Note 1, “Organization and Basis of Presentation.” Under these agreements, we incurred $40 million, net, and $94 million, net, for the three months ended September 30, 2024 and 2023, respectively, and $138 million, net, and $286 million, net, for the nine months ended September 30, 2024 and 2023, respectively. These amounts represent fees charged from GE and GE Vernova to the Company, the majority of which are related to information technology, and are net of fees charged from the Company to GE and GE Vernova for facilities and other shared services. For more information on these agreements, see Note 19, “Related Parties” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Current amounts due from and to GE under the various agreements are recognized within Due from related parties or Due to related parties, as applicable, in the Condensed Consolidated Statements of Financial Position. Non-current amounts due from GE were $70 million and $81 million, and due to GE were $41 million and $33 million, as of September 30, 2024 and December 31, 2023, respectively. These amounts were recognized within All other non-current assets and All other non-current liabilities, respectively, in the Condensed Consolidated Statements of Financial Position and primarily relate to tax and other indemnities. Following its separation from GE, GE Vernova does not meet the definition of a related party; accordingly, amounts as of September 30, 2024 due to and from GE Vernova in accordance with the TSA are excluded from the Due from related parties and Due to related parties financial statement line items and non-current balances disclosed above.

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS